Thrombolysis with alteplase administered within a narrow therapeutic window provides an
effective therapy for acute ischaemic stroke. However, mainly because of prehospital delay …

In acute stroke management, time is brain. Bringing swift treatment to the patient, instead of
the conventional approach of awaiting the patient's arrival at the hospital for treatment, is a …

Summary Background In September, 2008, the European Acute Stroke Study III (ECASS III)
randomised trial and the Safe Implementation of Treatment in Stroke-International Stroke …

Summary Background In the European Cooperative Acute Stroke Study III (ECASS III),
alteplase administered 3· 0–4· 5 h after the onset of stroke symptoms resulted in a significant …

Background Specialised CT-equipped mobile stroke treatment units shorten time to
intravenous thrombolysis in acute ischaemic stroke by starting treatment before hospital …

Background Tenecteplase is a modified tissue plasminogen activator with pharmacological
and practical advantages over alteplase—which is currently the only approved thrombolytic …

Background Early administration of intravenous recombinant tissue plasminogen activator (rt-
PA) after ischaemic stroke improves outcome. Previous analysis of combined data from …

For several years, the only therapy with proven efficacy for acute ischaemic stroke was
alteplase, which is approved for use within 4· 5 h after stroke onset in many countries, but …

Despite benefit in acute ischaemic stroke, less than 3% of patients receive tissue
plasminogen activator (tPA) in Australia. The FASTER (Face, Arm, Speech, Time …

Summary Background Mobile stroke units (MSUs) equipped with a CT scanner reduce time
to thrombolytic treatment and improve patient outcomes. We tested the hypothesis that …